A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
Acerta Pharma BV
Incyte Corporation
BerGenBio ASA
National Institutes of Health Clinical Center (CC)
Novartis
INSYS Therapeutics Inc